Fig. 4.

Replication of lifespan study with oral supplementation of C₆₀ in C57BL/6 J. Left panel: survival curves estimated by Kaplan-Meier in all C57BL/6 J mice treated with C₆₀-EVOO or EVOO versus untreated controls. Right panel: survival curves of the same mice subdivided in those starting the treatment with C60-EVOO or EVOO at the age of 9 months (C60 + EVOO_Y and EVOO_Y, respectively) and those starting the treatment at the age of 23 months (C60 + EVOO_O and EVOO_Y, respectively) versus untreated mice (Control). No significant differences in survival were detected among the experimental groups and between females and male mice. Analysis of survival curves starts at 21 months of age for all experimental groups. Respective numbers of mice at start are as follows: Controls n = 24 (12 F, 12 M); EVOO_Y n = 8 (4 F, 4 M); C60-EVOO_Y n = 8 (3 F, 5 M); EVOO_O n = 9 (5F, 4 M); C60-EVOO_O n = 10 (5F, 5 M)